Indication

Adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with cabozantinib and/or vandetanib.
Adults with advanced RET fusion-positive thyroid cancer (TC) who require systemic therapy following prior treatment with lenvatinib and/or sorafenib.

Medicine details

Medicine name:
selpercatinib (Retsevmo)
SMC ID:
SMC2370
Pharmaceutical company
Eli Lilly and Company Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
13 September 2021
SMC meeting date:
03 August 2021
Patient group submission deadline:
31 May 2021